Facebook
Twitter
LinkedIn
ForwardTesting template - virtual with Zoom
The clinical management of BCR-ABL1 negative myeloproliferative neoplasms (MPN) is advancing at a rapid pace. This activity covers the diagnosis, assessment of symptoms burden, and treatment of classical MPN such as polycythemia vera, essential thrombocytosis, and myelofibrosis. The discovery of driver mutations (eg. JAK2V617F) and delineation of the genetic basis of MPNs resulted in significant improvements in the management. ‘Update on the diagnosis of and management of myeloproliferative neoplasms’ is a CME-accredited virtual conference that brings together the leading experts in the United States to discuss recent advances in the management of MPN. This meeting will provide an opportunity to hear from the leading experts on recent advances in MPN, some of which will have immediate clinical applications. Furthermore, each session will also discuss novel emerging treatment options for MPN that may be available in the near future.
This virtual conference is intended to propagate new information to augment the knowledge and clinical competence of the cancer care providers in the following areas:
- Advances in the diagnosis and assessment of symptom burden in MPN
- Interferon and other novel treatment options for polycythemia and essential thrombocytosis
- Current approved JAK inhibitors for myelofibrosis and novel emerging treatment options
Target Audience
- Oncologists
- Residents/Fellows
- NPs/PAs
- Pharmacists
- Nurses
Registration fees:
Registration to this activity is free for healthcare providers who are NOT employees of ACCME defined ineligible companies (An ineligible company is any entity producing, marketing, re-selling, or distributing healthcare goods or services consumed by, or used on, patients with the exception of hospitals and facilities that provide direct care to patients). Please proceed to registration and select "non-industry learner" if you are a healthcare provider involved in patient care and are not an employee of an ineligible company.
If you are an employee of an ineligible company, please select "industry representative" and pay the industry registration fee when registering for this course.
Learning Objectives
Upon successful completion of this educational activity, participants will be able to:
- Review the updated diagnostic criteria and assessment of symptom burden in MPN and integrate into the clinical practice
- Identify the role of Interferon and other emerging novel treatment options for polycythemia and essential thrombocytosis
- Describe the currently approved agents and emerging novel targeted therapies for myelofibrosis
All times are listed in Pacific Standard Time (PST)
May 1, 2021
7:30 AM to 8:00 AM PST – Attendance/Registration
8:00 AM to 8:05 AM PST – Introduction
8:05 AM to 8:25 AM PST – Diagnosis and assessment of symptom burden in MPN
8:25 AM to 8:30 AM PST – Discussion
8:30 AM to 8:50 AM PST – Interferon and other novel treatment options for polycythemia and essential thrombocytosis
8:50 AM to 9:05 AM PST – Discussion
9:05 AM to 9:20 AM PST – Break
9:20 AM to 9:40 AM PST – JAKi therapy and emerging novel targeted therapies for Myelofibrosis
9:40 AM to 9:50 AM PST – Discussion
9:50 AM to 10:20 AM PST – Case-Based Discussion of MPN
10:20 AM to 10:25 AM PST – Adjourn
This meeting is held virtually on Zoom. Register for the activity to participate.
 | Mark Pegram, MDProfessor of Medicine Stanford University, Palo Alto, CA |  | Siddhartha Yadav, MDHematologist/Medical Oncologist Mayo Clinic, Rochester, MN |
 | Fenting Yan, MD, PhDHematologist/Medical Oncologist Swedish Cancer Institute, Seattle, WA |  | Hannah Linden, MDProfessor of Medicine University of Washington, Seattle, WA |
 | Roberto Leon-Ferre, MDHematologist/Medical Oncologist Mayo Clinic, Rochester, MN |
The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians.
The Binaytara Foundation designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the criteria for up to 2.0 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
Nursing Contact Hours
Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 2.0 Contact Hours.
ABSM Maintenance of Certificate Recognition Statement:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.0 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Available Credit
- 2.00 AMA PRA Category 1 Credit™The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 2.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 2.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
- 0.00 Attendance
- 2.00 Nursing Contact HoursProvider approved by the California Board of Registered Nursing, Provider # CEP17035, for 2.00 Contact Hours.
Please support this meeting by visiting our sponsors and exhibitors in the main exhibit breakout room during the exhibit presentations.
Please note that exhibit presentations are promotional materials separate from the accredited activities. These presentations are held in the exhibit breakout room during designated exhibit hours.
We encourage you to visit the main exhibit breakout room and each company's breakout rooms during exhibit and break hours.
The following Exhibitors will be making exhibit presentations during the exhibit hours:
| Company | Reps Presenting | Link to Exhibit Materials and Prescribing information |
|---|---|---|
Price
Registration Fees:
This activity is free for all healthcare providers who are not employees of an ineligible entity. Please select "non-industry learner" when you are ready to register for the course, and the price will reset to $0.
If you are employed by industry, you must pay a registration fee to participate in these meetings. Any unpaid registrations will be invoiced $350 per participant.
Cancellation Policy
You may cancel your enrollment at any time. No credits will be offered if you do not complete all required steps of this activity which include registration, participation in the live activity via Zoom, and completion of pre & post tests as well as course evaluations.
Refund Policy
This activity is free for all healthcare providers who are not employees of an ineligible entity.
No refunds will be issued if you are unable to attend the live meeting after enrollment.
Required Hardware/software
This activitywill be held virtually on Zoom. You will need access to internet and a hardware such as a laptop or desktop computer or a mobile device with Zoom application installed.
For best audio-visual experience, please update your Zoom application before joining the meeting.